GGrantIndex
← Leaderboards

Massachusetts General Hospital

Boston, MA

Compare ↔
$10,066,158,974
Total funding
7,546
Grants

Funding over time

peak $750M · FY2005–25
$1B$750M$500M$250M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,941,901,788 · 7393
CDC$36,659,487 · 14
NSF$35,261,773 · 72
AHRQ$31,680,256 · 46
FDA$20,655,670 · 19
SAMHSA$0 · 2

By mechanism

R01$4,952,788,524 · 2212
U01$908,157,729 · 167
P01$518,392,602 · 515
OT2$350,831,442 · 13
R21$339,527,152 · 766
K23$219,399,337 · 309

Investigators at Massachusetts General Hospital

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Fang Liu$4,711,9404 gr2Wei Zhou$3,785,1682 gr3David T. Miyamoto$3,300,0552 gr4Nicole R Zurcher Wimmer$2,825,6691 gr5Tommi Raij$2,674,7191 gr6Haobo Li$2,369,7123 gr7Chi-Fu Yang$2,348,2013 gr8David Fernando Aguillon$2,207,9814 gr

Emerging Leaders

6–10 yrs in

1Ana-Maria Vranceanu$15,910,16016 gr2Pradeep Natarajan$11,533,2347 gr3Heidi Irma Jacobs$10,716,3745 gr4Hailiang Huang$10,689,2172 gr5Shiqian Shen$9,623,22410 gr6Facundo Damian Batista$9,358,4754 gr7Xin Yu$7,364,6206 gr8Laura Diane Lewis$7,364,4724 gr

All-Time

Most funded here, all years

1Guillermo J. Tearney$41,716,06419 gr2Gary B. Ruvkun$40,968,5578 gr3Ralph Weissleder$40,693,50323 gr4Rakesh K. Jain$38,774,08513 gr5Jill M Goldstein$35,668,58213 gr6Bruce Fischl$32,997,45222 gr7Bradley T Hyman$32,263,98819 gr8Andrew T Chan$32,221,30710 gr

Largest grants

Interactive Data Portals and Robust Analytic Tools to Wrap PASC Cohorts (iDRAW) OTA-21-015A$109,664,903
OT2 · FY2021 · HL
Interactive Data Portals and Robust Analytic Tools to Wrap PASC Cohorts (iDRAW) OTA-21-015A$37,792,683
OT2 · FY2023 · HL
Interactive Data Portals and Robust Analytic Tools to Wrap PASC Cohorts (iDRAW) OTA-21-015A$32,649,961
OT2 · FY2024 · HL
Access for All in ALS (ALL ALS) East Clinical Coordinating Center$19,708,528
OT2 · FY2023 · NS
An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis$18,136,504
UF1 · FY2022 · NS
TAS::75 0872::TAS TRANSLATIONAL PROGRAM OF EXCELLENCE IN NANOTECHNOLOGY (MGH)$16,844,471
N01 · FY2010 · HL
DISCOVERY: Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY$16,362,355
U19 · FY2024 · NS
Access for All in ALS (ALL ALS) East Clinical Coordinating Center$15,032,251
OT2 · FY2024 · NS
Access for All in ALS (ALL ALS) East Clinical Coordinating Center$14,357,590
OT2 · FY2025 · NS
DISCOVERY: Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY$14,058,964
U19 · FY2021 · NS
DISCOVERY: Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY$13,954,895
U19 · FY2023 · NS
Point of Care Technology Research Center in Primary Care$13,847,931
U54 · FY2020 · EB
Administrative Supplement to Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)$13,774,000
U01 · FY2018 · HL
EPPIC-Net Pain Research - Application for Clinical Trial and Related Activities (OT2)$13,015,970
OT2 · FY2021 · NS
The New England Precision Medicine Consortium of the All of Us Research Program$12,000,000
OT2 · FY2018 · OD
The New England Precision Medicine Consortium of the All of Us Research Program$12,000,000
OT2 · FY2020 · OD
Prospective Study of the Gut Microbiome in Aging$11,749,351
RF1 · FY2020 · AG
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis$11,665,635
U01 · FY2024 · NS
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis$11,203,040
U01 · FY2023 · NS
DISCOVERY: Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY$11,092,441
U19 · FY2020 · NS